Skip to main content

Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM.

Publication ,  Journal Article
Jagannath, S; Abonour, R; Durie, BGM; Narang, M; Terebelo, HR; Gasparetto, CJ; Toomey, K; Hardin, JW; Wagner, L; Agarwal, A; Srinivasan, S ...
Published in: Blood Adv
July 10, 2018

Autologous stem cell transplantation (ASCT) followed by lenalidomide maintenance therapy is the standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). Clinical trials show progression-free survival (PFS) benefits, with some studies (Cancer and Leukemia Group [CALGB] trial and meta-analysis) also showing overall survival (OS) benefits, but applicability to real-world clinical settings is unclear. Using data from Connect MM, the largest US-based observational registry of NDMM patients, we analyzed effects of maintenance therapy on long-term outcomes in 1450 treated patients enrolled from 2009 to 2011. Patients who received induction therapy and ASCT (n = 432) were analyzed from 100 days post-ASCT (data cut 7 January 2016): 267 received maintenance (80% lenalidomide-based [of whom 88% received lenalidomide monotherapy]); 165 did not. Lenalidomide maintenance improved median PFS and 3-year PFS rate vs no maintenance (50.3 vs 30.8 months [hazard ratio (HR), 0.62; 95% confidence interval (CI), 0.46-0.82; P < .001] and 56% vs 42%, respectively). Improvements in median OS and 3-year OS rate were associated with lenalidomide maintenance vs no maintenance (not reached in either group [HR, 0.54; 95% CI, 0.36-0.83; P = .005] and 85% vs 70%, respectively). Five hematologic serious adverse events were reported with lenalidomide maintenance (pancytopenia [n = 2], febrile neutropenia, anemia, and thrombocytopenia [n = 1 each]) and 1 with no maintenance (thrombocytopenia). Second primary malignancies occurred at rates of 1.38 and 2.19 events per patient-year in lenalidomide maintenance and no maintenance groups, respectively. Survival benefits associated with lenalidomide maintenance previously demonstrated in clinical trials were observed in this community-based Connect MM Registry.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Blood Adv

DOI

EISSN

2473-9537

Publication Date

July 10, 2018

Volume

2

Issue

13

Start / End Page

1608 / 1615

Location

United States

Related Subject Headings

  • Time Factors
  • Survival Rate
  • Retrospective Studies
  • Registries
  • Multiple Myeloma
  • Middle Aged
  • Male
  • Maintenance Chemotherapy
  • Humans
  • Hematopoietic Stem Cell Transplantation
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Jagannath, S., Abonour, R., Durie, B. G. M., Narang, M., Terebelo, H. R., Gasparetto, C. J., … Rifkin, R. M. (2018). Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM. Blood Adv, 2(13), 1608–1615. https://doi.org/10.1182/bloodadvances.2018017186
Jagannath, Sundar, Rafat Abonour, Brian G. M. Durie, Mohit Narang, Howard R. Terebelo, Cristina J. Gasparetto, Kathleen Toomey, et al. “Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM.Blood Adv 2, no. 13 (July 10, 2018): 1608–15. https://doi.org/10.1182/bloodadvances.2018017186.
Jagannath S, Abonour R, Durie BGM, Narang M, Terebelo HR, Gasparetto CJ, et al. Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM. Blood Adv. 2018 Jul 10;2(13):1608–15.
Jagannath, Sundar, et al. “Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM.Blood Adv, vol. 2, no. 13, July 2018, pp. 1608–15. Pubmed, doi:10.1182/bloodadvances.2018017186.
Jagannath S, Abonour R, Durie BGM, Narang M, Terebelo HR, Gasparetto CJ, Toomey K, Hardin JW, Wagner L, Agarwal A, Srinivasan S, Kitali A, Flick ED, Sturniolo M, Rifkin RM. Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM. Blood Adv. 2018 Jul 10;2(13):1608–1615.

Published In

Blood Adv

DOI

EISSN

2473-9537

Publication Date

July 10, 2018

Volume

2

Issue

13

Start / End Page

1608 / 1615

Location

United States

Related Subject Headings

  • Time Factors
  • Survival Rate
  • Retrospective Studies
  • Registries
  • Multiple Myeloma
  • Middle Aged
  • Male
  • Maintenance Chemotherapy
  • Humans
  • Hematopoietic Stem Cell Transplantation